Share / Export Citation / Email / Print / Text size:

Postępy Mikrobiologii - Advancements of Microbiology

Polish Society of Microbiologists

Subject: Microbiology


ISSN: 0079-4252
eISSN: 2545-3149





Volume / Issue / page

Related articles

VOLUME 57 , ISSUE 4 (April 2018) > List of articles


Marta Prygiel / Klaudia Brodzik / Aldon Wiatrzyk / Małgorzata Główka / Katarzyna Woźnica / Karol Wdowiak / Urszula Czajka / Aleksandra A. Zasada *

Keywords : rotavirus, vaccines, gastroenteritis

Citation Information : Postępy Mikrobiologii - Advancements of Microbiology. Volume 57, Issue 4, Pages 0-0, DOI:

License : (CC BY-NC-ND 4.0)

Published Online: 24-May-2019



Rotavirus infections are a leading cause of severe gastroenteritis in children under five years of age. Before the introduction of vaccination for rotavirus,100–150 million cases of infections were recorded globally, resulting in 500 000 deaths. The first rotavirus vaccines were designed in the 1980s. In 2007, two oral rotavirus vaccines containing live attenuated strains were registered in Europe: the monovalent vaccine Rotarix (RV1) and the pentavalent vaccine Rotateq (RV5). The vaccines are available all over the world.
After the introduction of rotavirus vaccination, the number of infections decreased significantly and the number of deaths due to rotavirus gastroenteritis in children decreased over 50% globally. However, despite confirmed safety and effectiveness of the RV1 and RV5 vaccines, fear of vaccination against rotavirus infection still exists. It can be related to the bad reputation of the previous rotavirus vaccines, which were withdrawn from the market or were never introduced to the market due to unsatisfying clinical tests.

Content not available PDF Share



1. Albrecht P., Szajewska H.: Choroby przewodu pokarmowego u dzieci. WUM, Warszawa, 2011 s. 247 –225

2. Arora R., Swaminathan S.: Ready to measure impact? The introduction of Rotavirus Vaccine in India. Indian Pediatr. 53, 565–567 (2016)

3. Bernstein D.I., Sack D.A., Rothstein E., Reisinger K., Smith V.E., O’Sullivan D., Spriggs D.R., Ward R.L.: Efficacy of live, attenuated, human rotavirus vaccine 89–12 in infants: a randomised placebo-controlled trial. Lancet, 354, 287–290 (1999)

4. Bhandari N., Bhan M.K. i wsp.: Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet, 383, 2136–2143 (2014)

5. Bines J.E., Kirkwood C.D. i wsp.: Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo- -controlled trial. Lancet Infect. Dis. 15, 1389–1397 (2015)

6. Bishop R.F., Barnes G.L., Cipriani E., Lund J.S.: Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. New Engl. J. Med. 309, 72–76 (1983)

7. Brandt C.D., Parrott R.H. i wsp.: Pediatric viral gastroenteritis during eight years of study. J. Clin. Microbiol. 18, 71–78 (1983)

8. Breiman R.F., Zaman K., Armah G., Sow S.O., Anh D.D., Victor J.C., Hille D., Ciarlet M., Neuzil K.M.: Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine, 30 (Supl 1), 24–29 (2012)

9. Bresee J.S., Glass R.I., Ivanoff B., Gentsch J.R.: Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine, 17, 2207–2222 (1999)

10. Burnett E., Umesh P., Jacqueline T.: Rotavirus vaccines: Effectiveness, safety, and future directions. Pediatr. Drugs, 20, 223–233 (2018)

11. Centers for Disease Control and Prevention.: Intussusception among recipients of rotavirus vaccine – United States, 1998– 1999. MMWR Morb. Mortal. Wkly. Rep. 48, 577–581 (1999)

12. Centers for Disease control and Prevention.: Postmarketing monitoring of intussuspection after RotaTeq vaccination – United States, February 2007. MMWR Morb. Mortal. Wkly. Rep. 56, 218–222 (2007)

13. Centers for Disease Control and Prevention.: Rotavirus vaccine information statement, vis-statements/rotavirus.html (08.05.2018)

14. Centers for Disease Control and Prevention.: Suspection of Rotawirus vaccine after reports of intussuspection-United States, 1999. MMWR Morb. Mortal. Wkly. Rep. 53, 786–789 (2004)

15. Centre for Disease Control and Prevention.: Rotavirus surveillance – worldwide, MMWR Morb. Mortal. Wkly. Rep. 60, 514–516 (2009)

16. Charakterystyka Produktu Leczniczego Rotarix.: https:// (08.05.2018)

17. Charakterystyka Produktu Leczniczego RotaTeq.: https:// (08.05.2018)

18. Clark H.F., Bernstein D.I., Dennehy P.H.: Safety, efficacy and immunogenicity of live, quadrivalent human-bovine reasortant rotavirus vaccine in healthy infants. J. Pediatr. 144, 184–190 (2004)

19. Clark H.F., Burke C.J., Volkin D.B.: Safety, immunogenicity and eficacy in healthy infants of G1 and G2 human reasortant rotavirus vaccine in a new stabilizer.buffer liquid formulation. Pediatr. Infect. Dis. J. 22, 914–920 (2003)

20. Cook S.M., Glass R.I., LeBaron C.W., Ho M.S.: Global seasonality of rotavirus infections. Bull. World Health Organ. 68, 171–177 (1990)

21. Crawford S.E., Estes M.K. i wsp.: Rotavirus infection. Nat. Rev. Dis. Primers, 3, 17083 (2017)

22. Cunliffe N.A., Das B.K., Ramachandran M., Bhan M.K., Glass R.I., Gentsch J.R.: Sequence analysis demonstrates that VP6, NSP1 and NSP4 genes of Indian neonatal rotavirus strain 116E are of human origin. Virus Genes, 15, 39–44 (1997)

23. Cunliffe N.A., Dove W., Bunn J.E., Ben Ramadam M., Nyangao J.W., Riveron R.L., Cuevas L.E., Hart C.A.: Expanding global distribution of rotavirus serotype G9: detection in Libya, Kenya, and Cuba. Emerg. Infect. Dis. 7, 890 e2 (2001)

24. Cunliffe N.A., Kilgore P.E., Bresee J.S., Steele A.D., Luo N., Hart C.A., Glass R.I.: Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull. World Health Organ. 76, 525 e37 (1998)

25. Curns A.T., Steiner C.A., Barrett M., Hunter K., Wilson E., Parashar U.D.: Reduction in acute gastroenteritis hospitalizations among U.S. children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 U.S. states. J. Infect. Dis. 201, 1617–1624 (2010)

26. Czarnecki M., Gładysz A.: Zakażenia rotawirusowe. Puls Medycyny,,83427 (08.05.2018)

27. Danchin M., Kirkwood C.D., Lee K.J., Bishop R.F., Watts E., Justice F.A., Clifford V., Cowley D., Buttery J.P., Bines  J.E.: Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. Vaccine, 31, 2610–2016 (2013)

28. Dang D.A., Nguyen V.T., Vu D.T., Nguyen T.H., Nguyen D.M., Yuhuan W., Baoming J., Nguyen D.H., Le T.L., Rotavin-M1 Vaccine Trial Group.: A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. Vaccine, 30 (Supl 1), 114–121 (2012)

29. de Hoog M.L.A., Vesikari T., Giaquinto C., Huppertz  H.I., Martinon-Torres F., Bruijning-Verhagen P.: Report of the 5th European expert meeting on rotavirus vaccination (EEROVAC). Hum. Vaccin. Immunother. 14, 1027–1034 (2018)

30. De Vos B., Vesikari T., Linhares A.C., Salinas B., Pérez-Schael I., Ruiz-Palacios G.M., Guerrero Mde L., Phua K.B., Delem  A., Hardt K.: A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr. Infect. Dis. J. 23, 179–182 (2004)

31. Delem A., Lobmann M., Zygraich N.: A bovine rotavirus developed as a candidate vaccine for use in humans. J. Biol. Stand. 12, 443–445 (1984)

32. Dhingra M.S., Saluja T. i wsp.: Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine- -Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine, 32 (Supl 1), 117–123 (2014)

33. European Centre for Disease Prevention and Control.: ECDC Expert opinion on rotavirus vaccination in infancy. Stockholm: ECDC (2017)

34. Garbag-Chenon A., Fontaine J.L., Lasfargues G., Clark  H.F., Guyot J., Le Moing G., Hessel L., Bricout F.: Reactogenicity and immunogenicity of rotavirus WC3 vaccine in 5–12 month old infants. Res. Virol. 140, 207–217 (1989)

35. Gentsch, J. R., Glass R.I.: Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J. Infect. Dis. 192 (Supl  1), 146–159 (2005)

36. Gothefors L., Wadell G., Juto P., Taniguchi K., Kapikian A.Z., Glass R.I.: Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. J. Infect. Dis. 159, 753–757 (1989)

37. Groome M., Cryz S. i wsp.: Safety and immunogenicity of a parental P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in south Africa: a randomized, double-blind, placebo-controlled trial. Lancet Infect. Dis. 17, 843–853 (2017).

38. Heaton P.M., Ciarlet M.: The pentavalent rotavirus vaccine: Discovery to licensure and beyond. Vaccines, Stanley Plotkin. Clin. Infect. Dis. 45, 1618–1624 (2007)

39. Heliwich E.: Biegunki dziecięce (w) Choroby zakaźne i pasożytnicze – epidemiologia i profilaktyka, red. A. Baumann-Popczyk, M. Sadkowska-Todys, A. Zieliński, alfa-medica press, Bielsko- -Biała, 2014, s. 24–27

40. Hill H.A., Elam-Evans L.D., Yankey D., Singleton J.A., Dietz V.: Vaccination coverage among children aged 19–35 months –  United States, 2015. MMWR Morb. Mortal. Wkly. Rep. 65, 1065–1071 (2016)

41. Hjelt K., Grauballe P.C., Henriksen L., Krasilnikoff P.A.: Rotavirus infections among the staff of a general paediatric department. Acta Paediatr. Scand. 74, 617–618 (1985)

42. Hoshino, Y., Kapikian A.Z.: Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development. J. Health Popul. Nutr. 18, 5–14 (2000) (08.05.2018)

43. Isanaka S., Grais R.F. i wsp.: Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger. New Engl. J. Med. 376, 1121– 1130 (2017)

44. Jiang V., Jiang B., Tate J., Parashar U.D., Patel M.M.: Performance of rotavirus vaccines in developed and developing countries. Hum. Vaccines, 6, 532–542 (2010)

45. Jin-song L., Bing C., Han-chun G., Dan-di L., Lin L., LI-li L., Na L., Zhao-Jun D.: Faecal shedding of rotavirus vaccine in Chinese children after vaccination with Lanzhou lamb rotavirus vaccine. Scientific Reports, 8, 1001 (2008)

46. Joensuu J., Koskenniemi E., .Pang X.L., Vesikari T.: Randomised placebo-controlled trial of rhesus-human reasortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet, 350, 1205–1209 (1997)

47. Jonesteller C.L., Burnett E., Yen C., Tate J.E., Parashar  U.D.: Effectiveness of Rotavirus Vaccination: A systematic review of the first decade of global post-licensure data, 2006–2016. Clin. Infect. Dis. 65, 840–850 (2017)

48. Kang G., Kelkar S.D., Chitambar S.D., Ray P., Naik T.: Epidemiological profile of rotaviral infection in India: challenges for the 21st century. J. Infect. Dis. 192, 120–126 (2005)

49. Kapikian A., Hoshino Y.,Chanosk R., Perez-Schael I.: Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed ar preventing severe rotavirus diarrhoea in infants and young children. J. Infect. Dis. 174, 65–72 (1996)

50. Karafillakis E., Hassounah S., Atchison C.: Effectiveness and impact of rotavirus vaccines in Europe, 2006–2014. Vaccine, 33, 2097–2107 (2015)

51. Kirkwood CD, Ma LF, Carey ME, Steele AD.: The rotavirus vaccine development pipeline. Vaccine, DOI: 10.1016/j.vaccine. 2017.03.076 (2017).

52. Korycka M.: Epidemiologia zakażeń rotawirusowych u dzieci, Przegl. Epidemiol.

55, 275–279 (2001) 53. Kramer A., Schwebke I., Kampf G.: How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infectious Diseases, 16.08.2006, (10.04.2018)

54. Leino T., Ollgren J., Salo H., Tiihonen P., Kilpi T.: First year experience of rotavirus immunisation programme in Finland. Vaccine, 31, 176–182 (2012)

55. Lopez A.L., Raguindin P.F. i wsp.: Impact of rotavirus vaccine introduction in Agusan Del Sur, Philippines. Twelfth International Rotavirus Symposium, 7–9.09.2016 ,

56. Luna E.J., Frazatti-Gallina N.M., Timenetsky M.C., Cardoso M.R., Veras M.A., Miraglia J.L., Escobar A.M., Grisi S.J., Raw I., Precioso A.R.: A phase I clinical trial of a new 5- valent rotavirus vaccine. Vaccine, 31, 1100–1105 (2013)

57. Madhi S.A., Neuzil K.M. i wsp.: Effect of human rotavirus vaccine on severe diarrhea in African infants. New Engl. J. Med. 362, 289–298 (2010)

58. Meldunki Epidemiologiczne NIZP-PZH http://wwwold.pzh. (08.05.2018)

59. Moon S., Wang Y., Edens C., Gentsch J.R., Prausnitz  M.R., Jiang B.: Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch. Vaccine, 31, 3396–3402 (2013)

60. Mrukowicz J., Szajewska H., Vesikari T.: Options for the prevention of rotavirus disease other than vaccination. J. Pediatr. Gastr. Nutr. 46 (Supl 2), 32–37 (2008)

61. Mrukowicz J.: Szczepienie przeciwko rotawirusom w praktyce lekarskiej. Aktualny (2017) stan wiedzy. Medycyna Praktyczna – Szczepienia, 4, 64–86 (2017)

62. Murphy T., Gargiullo P.M., Wharton M.: More on rotavirus vaccination and intussuspection. New Eng. J. Med. 436, 564–572 (2002)

63. Naik S.P., Zade J.K., Sabale R.N., Pisal S.S., Menon R., Bankar S.G., Gairola S., Dhere R.M.: Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®) Vaccine, 35, 2962–2969 (2017)

64. Państwowa Inspekcja Sanitarna: Stan sanitarny kraju w roku 2016, (08.05.2018)

65. PATH: Phase I/II Descending Age Study of P2VP8 subunit parental rotavirus vaccine in Healthy Toddlers and Infants 2014, (08.05.2018)

66. Payne D.C., NVSN i wsp. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 U.S. counties, 2006–2009. Clin. Infect. Dis. 53, 245–253. (2011)

67. Penelope H.: Dennehy Rotavirus Vaccines: an Overview. Clin. Microbiol. Rev. 21 198–208 (2008)

68. Perez-Schael I., Gountinas M.J., Perez M., Pagone V., Rojas A.M., Gonzales R., Cunto W., Hoshino Y., Kapikan Z.: Efficacy of the rhesus rotavirus-based quadrivalnet vaccine in infants and Young children In Venezuela. New Engl. J. Med. 337, 1181–1187 (1997)

69. Pulkowska-Nowocień A., Prędota D., Topczewska-Cabanek A., Życińska K., Wardyn K.A., Nitsch-Osuch A.: Stan zaszczepienia dzieci przeciw rotawirusom w wybranej poradni Podstawowej Opieki Zdrowotnej w Warszawie w latach 2006–2013. Fam. Med. Primary Care Rev. 16, 353–355 (2014)

70. Ruiz-Palacios G.M., O’Ryan M. i wsp.: Safety and efficacy of a  nattenuated vaccine againstsevere rotavirus gastroenteritis. New Engl. J. Med. 354, 11–22 (2006)

71. Santos N., Hoshino Y.: Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol. 15, 29–56 (2005)

72. Santosham M., Davidson B.L. i wsp.: Efficacy and safety of high-dose rhesus-human reasortant rotavirus vaccine in native American populations. J. Pediatr. 131, 632–638 (1997)

73. Schwartz J.L.: The First Rotavirus Vaccine and the Politics of Acceptable Risk. Milbank Q. 90, 278–310 (2012)

74. Senturia Y.D., Peckham C.S., Cordery M., Chrystie I.A., Banatvala J.E., Abdree F.E.: Live attenuated oral ratavirus vaccine. Lancet, 2, 1091 (1987)

75. Tate J.E., Burton A.H., Boschi-Pinto C., Parashar U.D.: Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin. Infect. Dis. 62 (Supl 2), 96–105 (2016)

76. Trang V.N., Braeckman T., Lernout T., Hau T.V., Anhle T.K., Luan le T., Van Damme P., Anh D.D.: Prevalence of rotavirus antibodies in breast milk and inhibitory effects to rotavirus vaccines. Hum. Vacc. Immunother. 10, 3681–3687 (2014)

77. Velázquez F.R., Verstraeten T. i wsp.: Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr. Infect. Dis. J. 31, 736–744 (2012)

78. Vesikari T., Giaquinto C., Huppertz H.: Clinical trials of rotavirus vaccines in Europe. Pediatr. Infect. Dis. J. 25, 42–47(2006)

79. Vesikari T., Heaton M.D. i wsp.: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New Engl. J. Med. 354, 23–33 (2006)

80. Vesikari T., Isolauri E., D’Hondt E., Delem A., Zissis G.: Protection of infants againts rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet, 1, 977–981 (1984)

81. Vesikari T., Isolauri E., Delem A., d’Hondt E., André F.E., Beards  G.M., Flewett T.H.: Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine strain in infants vaccinated before rotavirus epidemic. J. Pediatr. 107, 189–194 (1985)

82. Vesikari T., Maki M., Isolauri E.: Epidemiologic beckground for the need of rotavirus vaccine in Finland: preliminary experience of RIT 4237 strain of live attenuated rotavirus vaccine in adults. Dev. Biol. Stand. 53, 229–236 (1983)

83. Vesikari T., Ruuska T., Delem A., Andre F.E.: Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine: a preliminary report. Pediatr. Infect. Dis. J. 6, 164–169 (1987)

84. Vesikari T., Ruuska T., Delem A., Andree F.E., Beards G.M., Flewett T.H.: Efficacy of two doses RIT 4237 bovine rotavirus vaccine (at birth and 7 months of age) for prevention of rotavirus diarrhoea. Acta Peadiatr. Scand. 80, 173–180 (1991)

85. World Health Organization: Rotavirus vaccines. WHO position paper – January 2013-Recomendations. Weekly Epidemiol. Rec. 88, 49–64 (2013)

86. Zaman K., Victor J.C. i wsp.: Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. Plos Med. 14, e1002282 (2017)

87. Zhen S.S., Wang X.Y. i wsp.: Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case-control design. Emerg. Microbes Infec. 4, e64 (2015)

88. Zieliński A.: Odporność zbiorowiskowa, (w) Wakcynologia, red. W. Magdzik, D. Naruszewicz-Lesiuk, A. Zieliński, alfa-medica press, Bielsko-Biała, 2007, s. 50–57